Analysis of risk factors and construction and validation of a predictive model for determining the risk of endometrial cancer in postmenopausal patients with abnormal uterine bleeding

The data of 174 postmenopausal patients with abnormal uterine bleeding admitted were assessed to determine associated risk factors and develop and validate a prediction model to evaluate the risk of endometrial cancer in these patients. The patients were divided into a study group and a control group, among which 62 patients were diagnosed with endometrial cancer. A binary logistic regression analysis model using multifactorial regression analysis was established, and a column line graph of the prediction model was created using the R software. The model’s goodness-of-fit test was performed using the Hosmer-Lemeshow test, and SPSS (version 27, International Business Machines Corporation, Armonk, NY, USA) was used to plot the receiver operating characteristic (ROC) curve to evaluate the model’s predictive value. Binary logistic multifactorial regression analysis revealed that elevated body mass index (BMI), human epididymal protein 4 (HE4), cancer antigen 125 (CA125), combined fibroids and thickened endometrial cancer were risk factors for endometrial cancer in patients with abnormal postmenopausal uterine bleeding, based on which a probability model for predicting the risk of developing endometrial cancer in patients with abnormal postmenopausal uterine bleeding was constructed, and represented as P = 1/[1 + exp (4.227 − 4.594X1 − 2.029X5 − 1.165X6 − 1.817X7 − 2.080X8)]. In addition, the goodness-of-fit test, assessed using Hosmer and Lemeshow, yielded an χ2 value of 14.253 and a p-value of 0.075. Furthermore, the ROC curve analysis demonstrated an area under the curve (AUC) of 0.993 (95% confidence interval (CI), 0.892–0.974; p < 0.05). In conclusion, elevated BMI, HE4 and CA125, along with the presence of combined fibroids and thickened endometrial lining, were identified as significant risk factors for endometrial cancer in postmenopausal patients with abnormal uterine bleeding. The risk prediction model developed in this study provides a scientifically sound approach to assess the risk of endometrial cancer in these patients.

Abnormal postmenopausal uterine bleeding; Endometrial cancer; Risk factors; Prediction model; Efficacy validation

[1] D’Urso S, Arumugam P, Weider T, Hwang LD, Bond TA, Kemp JP, et al. Mendelian randomization analysis of factors related to ovulation and reproductive function and endometrial cancer risk. BMC Medicine. 2022; 20: 419.

[2] Dou Y, Song K, Fu Y, Shen Y, Zhang C, Yao S, et al. Risk factors and prognosis of early recurrence in stage I–II endometrial cancer: a large-scale, multi-center, and retrospective study. Frontiers in Medicine. 2022; 9: 808037.

[3] Rebegea LF, Stoleriu G, Manolache N, Serban C, Craescu M, Lupu MN, et al. Associated risk factors of lower limb lymphedema after treatment of cervical and endometrial cancer. Experimental and Therapeutic Medicine. 2020; 20: 181.

[4] Wedin M, Stalberg K, Marcickiewicz J, Ahlner E, Ottander U, Åkesson Å, et al. Risk factors for lymphedema and method of assessment in endometrial cancer: a prospective longitudinal multicenter study. International Journal of Gynecologic Cancer. 2021; 31: 1416–1427.

[5] Otani S, Himoto Y, Nishio M, Fujimoto K, Moribata Y, Yakami M, et al. Radiomic machine learning for pretreatment assessment of prognostic risk factors for endometrial cancer and its effects on radiologists’ decisions of deep myometrial invasion. Magnetic Resonance Imaging. 2022; 85: 161–167.

[6] Pigott A, Obermair A, Janda M, Vagenas D, Ward LC, Reul-Hirche H, et al. Incidence and risk factors for lower limb lymphedema associated with endometrial cancer: results from a prospective, longitudinal cohort study. Gynecologic Oncology. 2020; 158: 375–381.

[7] Faber MT, Sperling CD, Bennetsen AKK, Aalborg GL, Kjaer SK. A Danish nationwide study of risk factors associated with type I and type II endometrial cancer. Gynecologic Oncology. 2021; 161: 553–558.

[8] Jin X, Yan R, Li Z, Zhang G, Liu W, Wang H, et al. Evaluation of amide proton transfer-weighted imaging for risk factors in stage I endometrial cancer: a comparison with diffusion-weighted imaging and diffusion kurtosis imaging. Frontiers in Oncology. 2022; 12: 876120.

[9] Gaudet Chardonnet A, Azaïs H, Ballester M, Raimond E, Bendifallah S, Ouldamer L, et al. Prognostic value and risk factors of peritoneal carcinomatosis recurrence for patients with endometrial cancer: a multicenter study from the FRANCOGYN group. Annals of Surgical Oncology. 2021; 28: 212–221.

[10] Lei M, Adambekov S, Edwards RP, Wang R, Yuan J, Kalix E, et al. Endometrial cancer risk factors in Singapore Chinese: a prospective cohort study. Annals of Epidemiology. 2022; 71: 9–14.

[11] Lin Q, Lu Y, Lu R, Chen Y, Wang L, Lu J, et al. Assessing metabolic risk factors for LVSI in endometrial cancer: a cross-sectional study. Therapeutics and Clinical Risk Management. 2022; 18: 789–798.

[12] Sarink D, Wilkens LR, White KK, Le Marchand L, Wu AH, Setiawan VW, et al. Racial/ethnic differences in anthropometric and hormone-related factors and endometrial cancer risk: the multiethnic cohort study. British Journal of Cancer. 2021; 124: 1724–1733.

[13] Bogani G, Papadia A, Buda A, Casarin J, Di Donato V, Plotti F, et al. Factors predicting morbidity in surgically-staged high-risk endometrial cancer patients. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2021; 266: 169–174.

[14] Pin S, Mateshaytis J, Ghosh S, Batuyong E, Easaw JC. Risk factors for venous thromboembolism in endometrial cancer. Current Oncology. 2020; 27: 198–203.

[15] Angeles MA, Migliorelli F, León Ramírez LF, Ros C, Perissinotti A, Tapias A, et al. Predictive factors of preoperative sentinel lymph node detection in intermediate and high-risk endometrial cancer. The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2023; 67: 37–45.

[16] Zhang Y, Liu H, Han X, Tang Y. Analysis of risk factors for sentinel lymph node metastasis in patients with endometrial cancer. American Journal of Translational Research. 2022; 14: 8650–8658.

[17] Washington CR, Haggerty A, Ronner W, Neff PM, Ko EM. Knowledge of endometrial cancer risk factors in a general gynecologic population. Gynecologic Oncology. 2020; 158: 137–142.

[18] Zhao J, Hu Y, Zhao Y, Chen D, Fang T, Ding M. Risk factors of endometrial cancer in patients with endometrial hyperplasia: implication for clinical treatments. BMC Women’s Health. 2021; 21: 312.

[19] Sponholtz TR, Palmer JR, Rosenberg L, Chen C, Chen Y, Clarke MA, et al. Risk factors for endometrial cancer in Black women. Cancer Causes & Control. 2023; 34: 421–430.

[20] Togami S, Kubo R, Kawamura T, Yanazume S, Kamio M, Kobayashi H. Risk factors for lymphatic complications following lymphadenectomy in patients with endometrial cancer. Taiwanese Journal of Obstetrics and Gynecology. 2020; 59: 420–424.

[21] Toprak S, Sahin EA, Sahin H, Tohma YA, Yilmaz E, Meydanli MM. Risk factors for cervical stromal involvement in endometrioid‐type endometrial cancer. International Journal of Gynecology & Obstetrics. 2021; 153: 51–55.

[22] Anderson EM, Luu M, Lu DJ, Chung EM, Kamrava M. Pathologic primary tumor factors associated with risk of lymph node involvement in patients with non-endometrioid endometrial cancer. Gynecologic Oncology. 2022; 165: 281–286.

[23] Shin W, Yang SJ, Park SY, Kang S, Lee DO, Lim MC, et al. A predictive model based on site-specific risk factors of recurrence regions in endometrial cancer patients. BMC Cancer. 2022; 22: 1111.

[24] Anic K, Flohr F, Schmidt MW, Krajnak S, Schwab R, Schmidt M, et al. Frailty assessment tools predict perioperative outcome in elderly patients with endometrial cancer better than age or BMI alone: a retrospective observational cohort study. Journal of Cancer Research and Clinical Oncology. 2023; 149: 1551–1560.

[25] Kurosu H, Todo Y, Yamada R, Minowa K, Tsuruta T, Minobe S, et al. A BMI-category distribution pattern of intrinsic and treatment-related prognostic factors in endometrial cancer. Japanese Journal of Clinical Oncology. 2021; 51: 722–727.

[26] Shang W, Zhang J, Song H, Zhu S, Zhang A, Hua Y, et al. Mechanism of tetrandrine against endometrial cancer based on network pharmacology. Drug Design, Development and Therapy. 2021; 15: 2907–919.

[27] Zhong Z, Guo X, Zheng Y. Network pharmacology-based and molecular docking analysis of resveratrol’s pharmacological effects on type I endometrial cancer. Anti-Cancer Agents in Medicinal Chemistry. 2022; 22: 1933–1944.

[28] Feng W, Jia N, Jiao H, Chen J, Chen Y, Zhang Y, et al. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer. Journal of Translational Medicine. 2021; 19: 51.

[29] Romera AE, Guardiola TC, Vielba MB, Torralba CD, Martin PCJ, Mainar LB. HE4 tumor marker as a predictive factor for lymphatic metastasis in endometrial cancer. International Journal of Gynecology & Obstetrics. 2020; 149: 265–268.

[30] LyBarger KS, Miller HA, Frieboes HB. CA125 as a predictor of endometrial cancer lymphovascular space invasion and lymph node metastasis for risk stratification in the preoperative setting. Scientific Reports. 2022; 12: 19783.